We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+1.9%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$559M
AUM Growth
-$480M
(-46%)
Cap. Flow
-$438M
Cap. Flow
% of AUM
-78.37%
Top 10 Holdings %
Top 10 Hldgs %
15.86%
Holding
756
New
216
Increased
66
Reduced
143
Closed
331
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALLK
Allakos
ALLK
|
+$25.1M |
| 2 |
Merck
MRK
|
+$9.57M |
| 3 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$9.37M |
| 4 |
BridgeBio Pharma
BBIO
|
+$9.02M |
| 5 |
Marvell Technology
MRVL
|
+$7.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$10.5M |
| 2 |
Citigroup
C
|
+$10.5M |
| 3 |
Microsoft
MSFT
|
+$9.87M |
| 4 |
OPTU
Optimum Communications Inc
OPTU
|
+$9.41M |
| 5 |
AES
AES
|
+$7.92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.93% |
| 2 | Consumer Discretionary | 17.95% |
| 3 | Healthcare | 12.14% |
| 4 | Communication Services | 8.7% |
| 5 | Financials | 8.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Agilent Technologies
A
$39.9B
| $974K | 0.17% |
6,109
-7,684
| -56% | -$1.2M |
|
177
Labcorp
LH
$25.4B
| $972K | 0.17% |
+3,603
| New | +$892K |
|
|
ABB
178
DELISTED
ABB Ltd
ABB
| $968K | 0.17% |
25,359
-41,310
| -62% | -$1.45M |
|
179
Best Buy
BBY
$17.8B
| $956K | 0.17% |
9,406
-46,991
| -83% | -$5.35M |
|
180
Qiagen
QGEN
$8.65B
| $951K | 0.17% |
16,139
+9,524
| +144% | +$546K |
|
|
DNB
181
DELISTED
Dun & Bradstreet
DNB
| $944K | 0.17% |
46,076
-17,723
| -28% | -$337K |
|
182
The RealReal
REAL
$1.52B
| $923K | 0.17% |
79,543
-147,346
| -65% | -$1.94M |
|
|
GAP
183
The Gap Inc
GAP
$7.4B
| $911K | 0.16% |
51,642
+24,938
| +93% | +$522K |
|
184
Norwegian Cruise Line
NCLH
$9.32B
| $899K | 0.16% |
+43,328
| New | +$1.04M |
|
185
Upwork
UPWK
$1.18B
| $899K | 0.16% |
+26,303
| New | +$1.16M |
|
186
Western Alliance Bancorporation
WAL
$9.05B
| $890K | 0.16% |
+8,267
| New | +$931K |
|
|
TWTR
187
DELISTED
Twitter, Inc.
TWTR
| $878K | 0.16% |
+20,311
| New | +$1.06M |
|
188
Unilever
UL
$139B
| $877K | 0.16% |
14,500
-2,981
| -17% | -$177K |
|
189
AMC Entertainment Holdings
AMC
$2.38B
| $870K | 0.16% |
+3,197
| New | +$1.13M |
|
190
Texas Roadhouse
TXRH
$13.7B
| $860K | 0.15% |
+9,633
| New | +$858K |
|
191
Ameren
AEE
$30.2B
| $838K | 0.15% |
+9,414
| New | +$800K |
|
192
CF Industries
CF
$17.9B
| $833K | 0.15% |
+11,774
| New | +$737K |
|
193
Ginkgo Bioworks
DNA
$612M
| $832K | 0.15% |
+2,502
| New | +$1.19M |
|
194
FirstEnergy
FE
$27.7B
| $832K | 0.15% |
20,006
+3,312
| +20% | +$128K |
|
195
Leggett & Platt
LEG
$1.4B
| $832K | 0.15% |
+20,222
| New | +$878K |
|
196
Perrigo
PRGO
$1.84B
| $820K | 0.15% |
21,092
-41,860
| -66% | -$1.76M |
|
197
Coherent
COHR
$64.2B
| $814K | 0.15% |
11,919
-27,424
| -70% | -$1.72M |
|
198
Trade Desk
TTD
$8.91B
| $802K | 0.14% |
8,747
-7,937
| -48% | -$695K |
|
199
Snowflake
SNOW
$110B
| $801K | 0.14% |
+2,366
| New | +$824K |
|
200
Calix
CALX
$2.42B
| $800K | 0.14% |
+10,005
| New | +$653K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q4 2021 Portfolio in Review
As of Q4 2021, Seven Eight Capital held 756 positions worth $559M, down 46% from $1.04B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Seven Eight Capital withdrew a net $438M in Q4 2021, closing 331 positions and reducing 143 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $10.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 23% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Seven Eight Capital opened a new position in Allakos worth $3M.
- Seven Eight Capital's largest Q4 2021 buy was Allakos: 306,723 shares worth $3M.
- Seven Eight Capital added most to Mimecast Limited in Q4 2021, an estimated $6.07M increase.
- Seven Eight Capital's biggest Q4 2021 reduction was Fidelity National Information Services, cutting an estimated $7.12M.
- Seven Eight Capital fully exited Bristol-Myers Squibb in Q4 2021, selling an estimated $10.5M.
- Seven Eight Capital's ten largest holdings make up 16% of its $559M portfolio in Q4 2021.
- Seven Eight Capital opened 216 new positions and closed 331 in Q4 2021.
- Seven Eight Capital's portfolio value fell 46% quarter-over-quarter to $559M.
Based on Seven Eight Capital's 13F filing for Q4 2021, filed 14 Feb 2022.